article thumbnail

Deliberate Dysentery

Codon

2 AP: A news story in Nature about your organization, 1Day Sooner, discussed some recent challenge trials involving the hepatitis C virus. When setting up a new challenge trial, you have to characterize the strain of the virus, bacteria or parasite and that's technically complicated. That's not coincidental.

Vaccine 132
article thumbnail

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.